Skip to main content
Research

Publications: Prof Chloe Orkin

Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2022 ) . Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London . Scientific Reports vol. 12 , ( 1 )
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A et al. ( 2022 ) . Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 . N Engl J Med
Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ et al. ( 2022 ) . HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe . HIV Medicine vol. 23 , ( 6 ) 684 - 692 .
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van Bremen K, Beniowski M, Mikhalik J et al. ( 2022 ) . The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study . HIV Medicine vol. 23 , ( 6 ) 585 - 598 .
Boffito M, Scarsi K, Orkin C ( 2022 ) . EDITORIAL: Is it time to implement injectable antiretroviral treatments globally? . Current Opinion in HIV and AIDS vol. 17 , ( 3 ) 119 - 120 .
Wohl D, Pozniak A, Workowski K, Haggins D, Daar E, Orkin C, Koenig E, Mounzer K et al. ( 2022 ) . B/F/TAF 5-year outcomes in treatment-naive adults . HIV MEDICINE . vol. 23 , 29 - 30 .
Campbell L, Ibrahim F, Barbini B, Samarawickrama A, Orkin C, Fox J, Waters L, Gilleece Y et al. ( 2022 ) . Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir . HIV Medicine vol. 23 , ( 4 ) 362 - 370 .
Daar E, Orkin C, Sax P, Koenig E, Clarke A, Baumgarten A, Brinson C, Huang H et al. ( 2022 ) . Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomly allocated to B/F/TAF, DTG/ABC/3TC or DTG + F/TAF after 3 years . HIV MEDICINE . vol. 23 , 12 - 12 .
Orkin C, Apea V ( 2022 ) . International Women's Day—how can I help? . The Lancet HIV vol. 9 , ( 4 ) e228 - e229 .
Dhairyawan R, Milner A, Thornhill J, Kwardem L, Matin N, Orkin C, Deane K ( 2022 ) . The acceptability of offering rapid antiretroviral therapy to people living with HIV in east London: a qualitative study . HIV MEDICINE . vol. 23 , 13 - 14 .
Fursa O, Mocroft A, Lazarus JV, Amele S, Lundgren J, Matulionyte R, Rasmussen LD, Rockstroh JK et al. ( 2022 ) . The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: Regional and intra-regional differences . AIDS vol. 36 , ( 3 ) 423 - 435 .
Lee MJ, Snell LB, Douthwaite ST, Fidler S, Fitzgerald N, Goodwin L, Hamzah L, Kulasegaram R et al. ( 2022 ) . Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study) . HIV Medicine vol. 23 , ( 2 ) 121 - 133 .
Orkin C, Cahn P, Castagna A, Emu B, Harrigan P, Kuritzkes DR, Nelson M, Schapiro J ( 2022 ) . Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV . HIV Medicine
Okhai H, Tariq S, Burns F, Gilleece Y, Dhairyawan R, Hill T, Peters H, Thorne C et al. ( 2021 ) . Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study . The Lancet HIV vol. 8 , ( 12 ) e747 - e754 .
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y et al. ( 2021 ) . Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials . Journal of Acquired Immune Deficiency Syndromes vol. 88 , ( 4 ) 393 - 398 .
Gupta N, Gilleece Y, Orkin C ( 2021 ) . Implementing U=U in clinical practice: Results of a British HIV association members survey . Sexually Transmitted Infections vol. 97 , ( 8 ) 619 - 620 .
Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S et al. ( 2021 ) . Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study . The Lancet HIV vol. 8 , ( 11 ) e668 - e678 .
Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H et al. ( 2021 ) . Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials . Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 73 , ( 8 ) 1440 - 1451 .
Pozniak A, Maggiolo F, Podzamczer D, Yazdanpanah Y, Gupta S, Esser S, Mounzer K, Grossberg R et al. ( 2021 ) . Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF . HIV MEDICINE . vol. 22 , 125 - 125 .
Pett S, McCabe L, Latifoltojar A, Post F, Fox J, Burns J, Pool E, Waters A et al. ( 2021 ) . Results of MAVMET, a multi-centre, open-label, 48-week randomised controlled trial of maraviroc with or without metformin for the treatment of non-alcoholic fatty liver disease in HIV-positive virologically suppressed adults . HIV MEDICINE . vol. 22 , 43 - 45 .
Molina JM, Orkin C, Cahn P, Lombaard J, Supparatpinyo K, Campbell H, Wan H, Teal V et al. ( 2021 ) . Safety and efficacy of doravirine in treatment-naive adults with HIV-1: 4 years of experience from the DRIVE-FORWARD and DRIVE-AHEAD clinical trials . HIV MEDICINE . vol. 22 , 29 - 30 .
Asad H, Collins IJ, Goodall RL, Crichton S, Hill T, Doerholt K, Foster C, Lyall H et al. ( 2021 ) . Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK . HIV Medicine vol. 22 , ( 8 ) 631 - 640 .
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ et al. ( 2021 ) . Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV . Journal of Antimicrobial Chemotherapy vol. 76 , ( 9 ) 2380 - 2393 .
Wan YI, Robbins AJ, Apea VJ, Orkin CM, Pearse R, Puthucheary ZA, Prowle JR ( 2021 ) . Ethnicity and acute hospital admissions: Multi-center analysis of routine hospital data . EClinicalMedicine101077 - 101077 .
Workowski K, Orkin C, Sax P, Hagins D, Koenig E, Stephens J, Gupta S, Huang H et al. ( 2021 ) . Four year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive adults . HIV MEDICINE . vol. 22 , 32 - 33 .
Wan YI, Apea VJ, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2021 ) . Ethnic disparities in hospitalisation and hospital-outcomes during the second wave of COVID-19 infection in east London . medrxiv
Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ et al. ( 2021 ) . Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults with Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial . Clinical Infectious Diseases vol. 73 , ( 1 ) 33 - 42 .
Cevik M, Haque SA, Manne-Goehler J, Kuppalli K, Sax PE, Majumder MS, Orkin C ( 2021 ) . Gender disparities in coronavirus disease 2019 clinical trial leadership . Clinical Microbiology and Infection vol. 27 , ( 7 ) 1007 - 1010 .
Orkin C, D'Amico R, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al. ( 2021 ) . Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 24 , 22 - 22 .
Pelchen-Matthews A, Borges ÁH, Reekie J, Rasmussen LD, Wiese L, Weber J, Pradier C, Degen O et al. ( 2021 ) . Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort . Journal of Acquired Immune Deficiency Syndromes vol. 87 , ( 2 ) 806 - 817 .
Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, D'Arminio Monforte A, Reiss P et al. ( 2021 ) . Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study . Annals of Internal Medicine vol. 174 , ( 6 ) 768 - 776 .
Zenner D ( 2021 ) . The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London . International Journal of Tuberculosis and Lung Disease
Nelson M, Winston A, Hill A, Mngqibisa R, Bassa A, Orkin C, Rassool M, Rodgers A et al. ( 2021 ) . Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine . AIDS (London, England) vol. 35 , ( 5 ) 759 - 767 .
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG et al. ( 2021 ) . Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study . The Lancet HIV vol. 8 , ( 4 ) e185 - e196 .
Penfold R, Arnold-Forster A, Orkin C ( 2021 ) . Redressing Gender Imbalance in Leadership in Academic Medicine . Academic Medicine vol. 96 , ( 4 )
Wan YI, Bien Z, Apea VJ, Orkin CM, Dhairyawan R, Kirwan CJ, Pearse RM, Puthucheary ZA et al. ( 2021 ) . Acute Kidney Injury in COVID-19: multicentre prospective analysis of registry data . Clinical Kidney Journalsfab071- - sfab071- .
Thornhill J, Orkin C ( 2021 ) . Long-acting injectable HIV therapies: the next frontier: Republication . Current opinion in HIV and AIDS vol. 16 , ( 2 ) 98 - 105 .
D'Amico R, Orkin C, Bernal Morell E, Tan DHS, Katner H, Singh Y, Stellbrink H-J, Belonosova E et al. ( 2021 ) . Safety and efficacy of cabotegravir plus rilpivirine long acting with and without oral lead-in: FLAIR week 124 results . INFECTION . vol. 49 , S7 - S7 .
Thornhill J, Orkin C ( 2021 ) . Long-acting injectable HIV therapies: The next frontier . Current Opinion in Infectious Diseases vol. 34 , ( 1 ) 8 - 15 .
Apea VJ, Wan YI, Dhairyawan R, Puthucheary ZA, Pearse RM, Orkin CM, Prowle JR ( 2021 ) . Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study . BMJ Open vol. 11 , ( 1 ) e042140 - e042140 .
Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al. ( 2021 ) . Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex with Men Living with Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom- . Clinical Infectious Diseases vol. 72 , ( 2 ) 233 - 238 .
Orkin C, Elion R, Thompson M, Rockstroh JK, Alvarez Bognar F, Xu ZJ, Hwang C, Sklar P et al. ( 2021 ) . Changes in weight and BMI with first-line doravirine-based therapy . AIDS (London, England) vol. 35 , ( 1 ) 91 - 99 .
Patel P, D'Amico R, Thiagarajah S, Wu S, Elliot E, Polli JW, Upadhyay O, Van Solingen-Ristea R et al. ( 2021 ) . WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS . SEXUAL HEALTH . vol. 18 , VI - VI .
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM et al. ( 2020 ) . Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials . Journal of Acquired Immune Deficiency Syndromes vol. 85 , ( 4 ) 498 - 506 .
van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses MA, Parks D, Angelis K et al. ( 2020 ) . Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials . Journal of acquired immune deficiency syndromes (1999) vol. 85 , ( 3 ) 325 - 330 .
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Liu YP, Wei X et al. ( 2020 ) . Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide versus comparators in cis-women and girls (living with HIV): an analysis of five clinical trials . HIV MEDICINE . vol. 21 , 18 - 19 .
Orkin C, Oka S, Philibert P, Brinson C, Bassa AC, Gusev D, Degen O, Gonzalez Garcia J et al. ( 2020 ) . Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results . HIV MEDICINE . vol. 21 , 14 - 14 .
Orkin C, Sax P, Arribas J, Gupta S, Martorell C, Stephens J, Stellbrink H-J, DeJesus E et al. ( 2020 ) . Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults . HIV MEDICINE . vol. 21 , 18 - 18 .
Andreatta K, Acosta R, D'Antoni M, Porter D, Chang S, Martin R, Willkom M, McNicholl I et al. ( 2020 ) . Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide . HIV MEDICINE . vol. 21 , 18 - 18 .
González-Cordón A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F et al. ( 2020 ) . Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease . Journal of Antimicrobial Chemotherapy vol. 75 , ( 11 ) 3334 - 3343 .
Orkin C, Molina J, Yazdanpanah Y, Chahin Anania C, DeJesus E, Eron J, Klopfer S, Grandhi A et al. ( 2020 ) . Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 51 - 52 .
Ibrahim F, Campbell L, Bailey AC, Stockwell S, Waters L, Orkin C, Johnson M, Gompels M et al. ( 2020 ) . Estimated glomerular filtration rate slopes on tenofovir alafenamide . HIV Medicine vol. 21 , ( 9 ) 607 - 612 .
Bradshaw D, Abramowicz I, Bremner S, Gilleece Y, Fedele S, Kirk S, Clarke C, Williams S et al. ( 2020 ) . Hepatic fibrosis in people with HIV and non-alcoholic fatty liver disease: baseline data from an open-label, feasibility randomised trial of maraviroc plus optimised background therapy (OBT) versus OBT alone . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 76 - 77 .
Orkin C ( 2020 ) . Novel ART compounds . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 10 - 10 .
D'Amico R, Orkin C, Bernal Morell E, Tan D, Katner H, Singh Y, Stellbrink H, Belonosova E et al. ( 2020 ) . Safety and efficacy of cabotegravir plus rilpivirine long-acting with and without oral lead-in: FLAIR Week 124 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 10 - 12 .
Chounta V, Wu S, Upadhyay O, Griffith S, Harrington C, Orkin C, Swindells S, Spreen W et al. ( 2020 ) . Subgroup analysis of patient-reported outcomes among participants in two phase III clinical trials of long-acting cabotegravir and rilpivirine (ATLAS and FLAIR) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 24 - 24 .
Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK et al. ( 2020 ) . Weight gain following initiation of antiretroviral therapy: Risk factors in randomized comparative clinical trials . Clinical Infectious Diseases vol. 71 , ( 6 ) 1379 - 1389 .
Mariot P, Orkin C, Elion R, Thompson M, Rockstroh J, Xu Z, Martin E, Hwang C et al. ( 2020 ) . Effet de la doravirine sur le poids et l’indice de masse corporelle chez les adultes VIH-1 débutant un traitement antirétroviral . Infectious Diseases Now vol. 50 , ( 6 )
Garvey L, Cooke G, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al. ( 2020 ) . Decline in HCV incidence in HIV positive MSM - progress to HCV micro-elimination in the UK? . JOURNAL OF HEPATOLOGY . vol. 73 , S32 - S33 .
Iwuji CC, Churchill D, Bremner S, Perry N, To Y, Lambert D, Bruce C, Waters L et al. ( 2020 ) . A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial . BMC Infectious Diseases vol. 20 , ( 1 )
Orkin C, Molina J-M, Yazdanpanah Y, Anania CC, DeJesus E, Eron J, Klopfer S, Grandhi A et al. ( 2020 ) . Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 23 , 15 - 16 .
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al. ( 2020 ) . Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection . Hepatology vol. 72 , ( 1 ) 7 - 18 .
Apea V, Wan Y, Dhairyawan R, Puthucheary Z, Pearse R, Orkin C, Prowle J ( 2020 ) . Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study . medrxiv
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ et al. ( 2020 ) . Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials . The Lancet HIV vol. 7 , ( 6 ) e389 - e400 .
Wan Y, Apea V, Dhairyawan R, Orkin C, Pearse RM, Prowle JR ( 2020 ) . ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London .
Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T et al. ( 2020 ) . Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation . HIV Medicine vol. 21 , ( 5 ) 309 - 321 .
Orkin C, Goddard SL ( 2020 ) . Enrolling pregnant women with HIV into clinical trials . The Lancet HIV vol. 7 , ( 5 ) e302 - e303 .
Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al. ( 2020 ) . Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients . AIDS vol. 34 , ( 5 ) 707 - 718 .
Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A et al. ( 2020 ) . Once-daily doravirine for initial treatment of adults living with human immunodeficiency virus-1: An integrated safety analysis . Clinical Infectious Diseases vol. 70 , ( 7 ) 1336 - 1343 .
Orkin C, Molina JM, Lombaard J, Dejesus E, Rodgers A, Kumar S, Martin E, Hanna G et al. ( 2020 ) . Once-daily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: An integrated efficacy analysis . Clinical Infectious Diseases vol. 70 , ( 7 ) 1344 - 1352 .
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S et al. ( 2020 ) . Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection . New England Journal of Medicine vol. 382 , ( 12 ) 1124 - 1135 .
Orkin C, Molina JM, Lombaard ( 2020 ) . Erratum: Oncedaily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: An integrated efficacy analysis (Clinical Infectious Diseases DOI: 10.1093/cid/ciz424) . Clinical Infectious Diseases vol. 70 , ( 2 )
Cevik M, Orkin C, Sax PE ( 2020 ) . Emergent resistance to dolutegravir among instinaive patients on first-line or second-line antiretroviral therapy: A review of published cases . Open Forum Infectious Diseases vol. 7 , ( 6 )
Cevik M, Orkin C ( 2019 ) . Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents . Expert Opinion on Investigational Drugs vol. 28 , ( 12 ) 1021 - 1024 .
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al. ( 2019 ) . Impact of early antiretroviral treatment on sexual behaviour: A randomised comparison . AIDS vol. 33 , ( 15 ) 2337 - 2350 .
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al. ( 2019 ) . Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison . AIDS vol. 33 , ( 15 ) 2337 - 2350 .
Martin EA, Hwang C, Orkin C ( 2019 ) . Reply to Lanzafame et al . Clinical Infectious Diseases vol. 69 , ( 10 ) 1832 - 1833 .
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT et al. ( 2019 ) . Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV . J Virus Erad vol. 5 , ( 4 ) 204 - 211 .
Quercia R, Orkin C, D'Amico R, Mrus J, Wu S, Cutrell A, Chow K, Polli J et al. ( 2019 ) . EACS 2019-Abstract Book . HIV MEDICINE . vol. 20 , 3 - 3 .
Orkin C, Elion R, Thompson M, Rockstroh J, Xu ZJ, Martin EA, Hwang C, Sklar P et al. ( 2019 ) . Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1 . HIV MEDICINE . vol. 20 , 7 - 8 .
Orkin C, Kityo C, Koenig E, Natukunda E, Ajana F, Gandhi-Patel B, Liu Y, Wei L et al. ( 2019 ) . Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials . HIV MEDICINE . vol. 20 , 22 - 22 .
Orkin C, Sax PE, Arribas J, Gupta S, Martorell C, Stephens JL, Stellbrink H-J, Dejesus E et al. ( 2019 ) . Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults . HIV MEDICINE . vol. 20 , 94 - 95 .
Stellbrink H-J, Post FA, Podzamczer D, Arribas J, Cua E, Molina J-M, Orkin C, Rockstroh JK et al. ( 2019 ) . Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older . HIV MEDICINE . vol. 20 , 138 - 138 .
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V et al. ( 2019 ) . Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 . Antiviral Research vol. 170 ,
Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS et al. ( 2019 ) . Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction . Clin Infect Dis vol. 69 , ( 7 ) 1136 - 1143 .
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K et al. ( 2019 ) . Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies . The Lancet HIV vol. 6 , ( 9 ) e576 - e587 .
Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, Dejesus E, Petrovic R, Luo D et al. ( 2019 ) . Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: Subgroup analyses of the phase 3 EMERALD study . AIDS Research and Therapy vol. 16 , ( 1 )
Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ et al. ( 2019 ) . Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials . AIDS vol. 33 , ( 9 ) 1455 - 1465 .
Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al. ( 2019 ) . Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016 . Eurosurveillance vol. 24 , ( 27 )
Orkin C ( 2019 ) . Does less equal more yet? . The Lancet HIV vol. 6 , ( 7 ) e412 - e413 .
Cullen L, Grenfell P, Rodger A, Orkin C, Mandal S, Rhodes T ( 2019 ) . 'Just another vial': A qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK . BMJ Open vol. 9 , ( 4 )
Podzamczer D, Stellbrink H-J, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. ( 2019 ) . B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results . HIV MEDICINE . vol. 20 , 18 - 18 .
Van Wyk J, Orkin C, Rubio-Garcia R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al. ( 2019 ) . Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies . HIV MEDICINE . vol. 20 , 18 - 19 .
Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP et al. ( 2019 ) . Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA . HIV Medicine vol. 20 , ( 4 ) 264 - 273 .
Orkin C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, Overton ET, Girard P-M, Oka S, D'Amico R et al. ( 2019 ) . Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results . HIV MEDICINE . vol. 20 , 6 - 7 .
Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al. ( 2019 ) . THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection . Journal of Hepatology . vol. 70 ,
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C et al. ( 2019 ) . Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance . Journal of Antimicrobial Chemotherapy vol. 74 , ( 3 ) 746 - 753 .
Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L et al. ( 2019 ) . Doravirine/Lamivudine/Tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: Week 48 results of the DRIVE-AHEAD Trial . Clinical Infectious Diseases vol. 68 , ( 4 ) 535 - 544 .
Finnerty F, Azad Y, Orkin C ( 2019 ) . Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services . The Lancet HIV vol. 6 , ( 2 )
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E et al. ( 2019 ) . Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: Final 96-week results of the NEAT022 study . Clinical Infectious Diseases vol. 68 , ( 4 ) 597 - 606 .
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK et al. ( 2019 ) . Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials . The Lancet vol. 393 , ( 10167 ) 143 - 155 .
Orkin C, Porteiro N, Berhe M, Dretler R, Viciana P, Tseng Y, Oprea C, Johnson M et al. ( 2019 ) . Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies . Journal of Infection and Public Health . vol. 12 ,
Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S, Lathouwers E, Hufkens V et al. ( 2018 ) . 1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s65 - s65 .
Orkin C, Squires K, Molina J-M, Sax P, Wong W, Sussmann O, Lin G, Kumar S et al. ( 2018 ) . LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial . Open Forum Infectious Diseases vol. 5 , ( suppl_1 ) s759 - s759 .
Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J et al. ( 2018 ) . Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials . HIV Medicine vol. 19 , ( 10 ) 724 - 733 .
Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA et al. ( 2018 ) . Chronic kidney disease risk in African and Caribbean populations with HIV . Journal of Infectious Diseases vol. 218 , ( 11 ) 1767 - 1772 .
Podzamczer D, Stellbrink H, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. ( 2018 ) . B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,
Orkin C, Eron J, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al. ( 2018 ) . Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,
Orkin C, Lampe F, Izambert C, Waters L ( 2018 ) . Mental health and HIV: what we all need to know . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 21 ,
Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL et al. ( 2018 ) . Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection . Journal of Viral Hepatitis vol. 25 , ( 10 ) 1180 - 1188 .
Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R et al. ( 2018 ) . Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study . Clinical Infectious Diseases vol. 67 , ( 7 ) 1010 - 1017 .
Cresswell FV, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR ( 2018 ) . A systematic review of risk of HIV transmission through biting or spitting: implications for policy . HIV Medicine vol. 19 , ( 8 ) 532 - 540 .
Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J et al. ( 2018 ) . A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients . AIDS vol. 32 , ( 11 ) 1431 - 1442 .
Cevik M, Orkin C ( 2018 ) . Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate . Current Opinion in HIV and AIDS vol. 13 , ( 4 ) 315 - 319 .
Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A et al. ( 2018 ) . Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health . J Virus Erad vol. 4 , ( 3 ) 196 - 207 .
Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA, Ainsworth J et al. ( 2018 ) . A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study . The Lancet HIV vol. 5 , ( 6 ) e301 - e308 .
Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C ( 2018 ) . Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department-uncovering the iceberg? . Epidemiology and Infection vol. 146 , ( 8 ) 1026 - 1035 .
Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al. ( 2018 ) . Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe . HIV Medicine vol. 19 , ( 5 ) 324 - 338 .
Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O'Shea S, Delpech V et al. ( 2018 ) . Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control . Journal of Infectious Diseases vol. 217 , ( 10 ) 1522 - 1529 .
Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C et al. ( 2018 ) . Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data . AIDS Research and Therapy vol. 15 , ( 1 )
Cresswell F, Ellis J, Hartley J, Sabin C, Brook G, Orkin C, Churchill D ( 2018 ) . A systematic review of risk of HIV transmission through biting or spitting: implications for policy . HIV MEDICINE . vol. 19 , S43 - S43 .
Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al. ( 2018 ) . Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort . HIV Medicine vol. 19 , ( 4 ) 252 - 260 .
Orkin C, Libre J, Kahl L, Blair E, Wynne B, Curtis L, Angelis K, Shah R et al. ( 2018 ) . Renal, Inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies . HIV MEDICINE . vol. 19 , S17 - S17 .
Orkin C, Khuong-Josses M-A, Lutz T, Baker D, Rubio R, Blair E, Kahl L, Angelis K et al. ( 2018 ) . Safety and efficacy of DTG plus RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location . HIV MEDICINE . vol. 19 , S28 - S29 .
Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al. ( 2018 ) . Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens . HIV Medicine vol. 19 , ( 2 ) 102 - 117 .
Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al. ( 2018 ) . The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people . HIV Medicine vol. 19 , ( 2 ) 90 - 101 .
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E et al. ( 2018 ) . Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial . The Lancet HIV vol. 5 , ( 1 ) e23 - e34 .
Orkin C, Llibre JM, Gallien S, Antinori A, Behrens GMN, Carr A ( 2018 ) . Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence . HIV Medicine vol. 19 , ( 1 ) 18 - 32 .
Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K et al. ( 2018 ) . Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study . Antiviral Therapy vol. 23 , ( 5 ) 405 - 413 .
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A et al. ( 2017 ) . Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study . The Lancet HIV vol. 4 , ( 12 ) e536 - e546 .
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I et al. ( 2017 ) . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial . The Lancet vol. 390 , ( 10107 ) 2063 - 2072 .
Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN et al. ( 2017 ) . A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada . HIV Medicine vol. 18 , ( 9 ) 655 - 666 .
Martinello M, Bhagani S, Gane EJ, Orkin C, Cooke G, Kulasegaram R, Shaw D, Hellard M et al. ( 2017 ) . Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study . HEPATOLOGY . vol. 66 , 574A - 575A .
Orkin C, Molina J-M, Gallant J, Negredo E, Gathe J, Eron J, Van Landuyt E, Lathouwers E et al. ( 2017 ) . Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults . Open Forum Infectious Diseases vol. 4 , ( Suppl 1 ) s737 - s738 .
Gourlay A, Fox J, Gafos M, Fidler S, Nwokolo N, Clarke A, Gilson R, Orkin C et al. ( 2017 ) . A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England . BMJ Open vol. 7 , ( 8 )
Pasvol TJ, Orkin C ( 2017 ) . Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: A retrospective analysis of sexual health screening in East London . Sexually Transmitted Infections vol. 93 , ( 5 )
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al. ( 2017 ) . A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48 . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 20 , 103 - 104 .
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C et al. ( 2017 ) . An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs . Journal of Antimicrobial Chemotherapy vol. 72 , ( 7 ) 2075 - 2082 .
O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A et al. ( 2017 ) . Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study . The Lancet HIV vol. 4 , ( 7 ) e295 - e302 .
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J et al. ( 2017 ) . Brief Report: Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults . Journal of Acquired Immune Deficiency Syndromes . vol. 75 , 226 - 231 .
Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR et al. ( 2017 ) . Safety and efficacy of ombitasvir, paritaprevir with ritonavir ± dasabuvir with or without ribavirin in patients with human immunodeficiency virus-1 and hepatitis c virus genotype 1 or genotype 4 coinfection: TURQUOISE-I part 2 . Open Forum Infectious Diseases vol. 4 , ( 3 )
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al. ( 2017 ) . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort . Clinical Infectious Diseases vol. 64 , ( 10 ) 1413 - 1421 .
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B et al. ( 2017 ) . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study . The Lancet HIV vol. 4 , ( 5 ) e195 - e204 .
Howarth AR, Burns FM, Apea V, Jose S, Hill T, Delpech VC, Evans A, Mercer CH et al. ( 2017 ) . Development and application of a new measure of engagement in out-patient HIV care . HIV Medicine vol. 18 , ( 4 ) 267 - 274 .
McNulty M, Orkin C, Smith C, Marshall N, Swaden L, Burns F ( 2017 ) . Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT) . HIV MEDICINE . vol. 18 , 17 - 18 .
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. ( 2017 ) . Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks . HIV MEDICINE . vol. 18 , 21 - 21 .
Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A et al. ( 2017 ) . Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom . HIV Medicine vol. 18 , ( 3 ) 204 - 213 .
Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T et al. ( 2016 ) . Clinical characteristics and outcomes of HIV-associated immune complex kidney disease . Nephrology Dialysis Transplantation vol. 31 , ( 12 ) 2099 - 2107 .
El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A et al. ( 2016 ) . HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK . Journal of Antimicrobial Chemotherapy vol. 71 , ( 12 ) 3487 - 3494 .
Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnsone M, Beeching NJ et al. ( 2016 ) . Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy . AIDS vol. 30 , ( 17 ) 2617 - 2624 .
Dhairyawan R, O'Connell R, Flanagan S, Wallis E, Orkin C ( 2016 ) . Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: The 'Going Viral' campaign . Sexually Transmitted Infections vol. 92 , ( 7 )
Barr E, Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G et al. ( 2016 ) . High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study . JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY . vol. 31 , 66 - 66 .
Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Yan M, Abram ME et al. ( 2016 ) . Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,
Marshall N, McNulty M, Smith C, Swaden L, Burns F, Orkin C ( 2016 ) . Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT) . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. ( 2016 ) . Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,
Shepherd L, Borges H, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J et al. ( 2016 ) . Infection-related and -unrelated malignancies, HIV and the aging population . HIV Medicine vol. 17 , ( 8 ) 590 - 600 .
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S et al. ( 2016 ) . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 . HIV Medicine vol. 17 , s2 - s104 .
Hughes RA, Sterne JAC, Walsh J, Post F, Nelson M, Jose S, Hill T, Tilling K et al. ( 2016 ) . Predicting virological decay in patients starting combination antiretroviral therapy . AIDS vol. 30 , ( 11 ) 1817 - 1827 .
Rodger A, Lampe F, Burman W, Gruhlich A, Friedland G, El-Sadr W, Neaton J, Emery S et al. ( 2016 ) . Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial . JOURNAL OF THE INTERNATIONAL AIDS SOCIETY . vol. 19 ,
Orkin C, Rjinders B, Stephan C, McKellar M, Kiertiburanakul S, Arribas J, Murphy D, Bloch M et al. ( 2016 ) . P045 Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): week 48 data in virologically suppressed adults . Sexually Transmitted Infections . vol. 92 , a34.1 - a3a34 .
Williams AJ, Wallis E, Orkin C ( 2016 ) . HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients? . International Journal of STD and AIDS vol. 27 , ( 7 ) 537 - 542 .
Orkin C, Jeffery-Smith A, Foster GR, Tong CYW ( 2016 ) . Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women? . BMJ Open vol. 6 , ( 5 ) e010661 - e010661 .
Bath R, O'Connell R, Lascar M, Ferrand R, Strachan S, Matin N, Bassnet I, Orkin C ( 2016 ) . TestMeEast: A campaign to increase HIV testing in hospitals and to reduce late diagnosis . AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV vol. 28 , ( 5 ) 608 - 611 .
Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S, Fisher M, Gazzard B et al. ( 2016 ) . Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation . HIV Medicine vol. 17 , ( 5 ) 368 - 372 .
Umaipalan A, Jayakumar A, Patel M, Wallis E, Baily G, Orkin C ( 2016 ) . Early virological response did not predict high levels of sustained virological response at 12 weeks (SVR12) in HIV/HCV-co-infected patients treated with directly acting agent (DAA)-containing therapy . HIV MEDICINE . vol. 17 , 45 - 45 .
Stohr W, Dunn D, Arenas-Pinto A, Paton N, Orkin C, Clarke A, Williams I, Johnson M et al. ( 2016 ) . Factors associated with virological rebound in patients receiving protease inhibitor monotherapy in the PIVOT trial . HIV MEDICINE . vol. 17 , 11 - 11 .
Orkin C, Clarke A, Gallant J, Daar E, Raffi F, Antonucci S, Mingjin Y, Chang A et al. ( 2016 ) . Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults . HIV MEDICINE . vol. 17 , 18 - 18 .
Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al. ( 2016 ) . Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: The "Going Viral" campaign . HIV Medicine vol. 17 , ( 3 ) 222 - 230 .
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D et al. ( 2016 ) . Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals . Medicine (United States) vol. 95 , ( 41 )
( 2016 ) . International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK . J Int AIDS Soc vol. 19 , ( 8(Suppl 7) )
Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K et al. ( 2016 ) . Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study . Medicine (United States) vol. 95 , ( 40 )
( 2016 ) . Oral abstracts of the 21st International AIDS Conference 18-22 July 2016, Durban, South Africa . J Int AIDS Soc vol. 19 , ( 6 Suppl 5 )
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M et al. ( 2016 ) . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study . The Lancet Infectious Diseases vol. 16 , ( 1 ) 43 - 52 .
Orkin C, Wallis E ( 2015 ) . Should HIV testing week be blood-borne-virus testing week? . The Lancet HIV vol. 2 , ( 12 ) e510 - e511 .
Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al. ( 2015 ) . The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy . AIDS vol. 29 , ( 17 ) 2269 - 2278 .
Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ et al. ( 2015 ) . Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study . PLoS ONE vol. 10 , ( 10 )
Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees? . Epidemiology and Infection vol. 143 , ( 13 ) 2837 - 2840 .
Podlekareva D, Grint D, Karpov I, Vassilenko A, Rakmanova A, Mansinho K, Chentsova N, Kravchenko E et al. ( 2015 ) . Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study . HIV Medicine vol. 16 , ( 9 ) 533 - 543 .
Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F et al. ( 2015 ) . Protease inhibitor monotherapy for long-term management of HIV infection: A randomised, controlled, open-label, non-inferiority trial . The Lancet HIV vol. 2 , ( 10 ) e417 - e426 .
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS et al. ( 2015 ) . Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial . The Lancet HIV vol. 2 , ( 8 ) e319 - e327 .
Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL ( 2015 ) . Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected with Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes . Journal of Infectious Diseases . vol. 212 , 367 - 377 .
Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P et al. ( 2015 ) . Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals . Philosophical Transactions of the Royal Society B: Biological Sciences vol. 370 , ( 1676 )
Thornhill J, Sivaramakrishnan A, Orkin C ( 2015 ) . Pneumococcal vaccination in people living with HIV . Vaccine vol. 33 , ( 28 ) 3159 - 3160 .
Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M et al. ( 2015 ) . Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals . AIDS vol. 29 , ( 10 ) 1205 - 1215 .
Wallis E, Thornhill J, Saunders J, Orkin C ( 2015 ) . Introducing opt-out HIV testing in an acute medical admissions unit: Does it improve testing uptake in those with lobar pneumonia? . Sexually Transmitted Infections vol. 91 , ( 3 )
Bath R, Ahmad K, Orkin C ( 2015 ) . Routine HIV testing within the emergency department of a major trauma centre: A pilot study . HIV Medicine vol. 16 , ( 5 ) 326 - 328 .
Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al. ( 2015 ) . Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy . AIDS vol. 29 , ( 7 ) 801 - 809 .
Deayton J, O'Sullivan E, McKnight A, Groves K, Bibby D, Clark D, Orkin C, Reeves I et al. ( 2015 ) . Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy . HIV MEDICINE vol. 16 , 20 - 20 .
Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY ( 2015 ) . P1247 : Unexpected high prevalence of HCV-viraemia (HCVRNA+) in the emergency department (ED) of a London hospital - should we be screening for HCV in ED attendees? . Journal of Hepatology . vol. 62 ,
Wallis E, Umaipalan A, Flanagan S, Montoto S, Orkin C ( 2015 ) . Post chemotherapy liver dysfunction and reactivation of Hepatitis B (HBV) and C (HCV) in an HIV-infected cohort . HIV MEDICINE vol. 16 , 41 - 41 .
Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A et al. ( 2015 ) . Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, open-label, non-randomised, phase 3 study . The Lancet vol. 385 , ( 9973 ) 1098 - 1106 .
Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D et al. ( 2015 ) . Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study . PLoS Medicine vol. 12 , ( 3 )
ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW ( 2015 ) . High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees? . Epidemiology and Infection
Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R et al. ( 2015 ) . A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals . PLoS ONE vol. 10 , ( 2 )
( 2015 ) . 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) . J Int AIDS Soc vol. 18 , ( 5 Suppl 4 )
( 2015 ) . HIV Drug Therapy in the Americas 16-18 April 2015, Mexico City, Mexico . J Int AIDS Soc vol. 18 , ( 3 Suppl 2 )
Orkin C, Umaipalan A ( 2015 ) . NtRTI sparing in patients at risk of bone disease . The Lancet HIV vol. 2 , ( 11 ) e452 - e453 .
Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A et al. ( 2014 ) . Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV Genotype 1 and HIV-1: A Phase 3 study . Clinical Infectious Diseases vol. 59 , ( 11 ) 1579 - 1587 .
Flanagan S, Crawford-Jones A, Orkin C ( 2014 ) . Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection . Expert Review of Clinical Pharmacology vol. 7 , ( 6 ) 691 - 704 .
Krupiczojc M, Goldsmith P, Cerio R, Orkin C, Williams E, Harwood C ( 2014 ) . Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease . BRITISH JOURNAL OF DERMATOLOGY . vol. 171 , 101 - 102 .
Bath R, O'Connell R, Lascar M, Ferrand R, Matin N, Basnett I, Apea V, Phiri E et al. ( 2014 ) . #TestMeEast@EuroHIVTestingWeek: a celebrity-endorsed, newsworthy NHS campaign across six hospitals to test 2500 patients (500/day) based in outpatients (OPD) and emergency departments (ED): the results . HIV MEDICINE . vol. 15 , 95 - 95 .
Wikeley S, Bradbury R, Bath R, O'Connell R, Matin N, Saunders J, Lascar M, Phiri E et al. ( 2014 ) . 'Legion' of medical students participates in largest hospital-based HIV testing week initiative - breaking down testing barriers in the doctors of tomorrow . HIV MEDICINE . vol. 15 , 91 - 91 .
Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S et al. ( 2014 ) . Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 pooled ECHO/THRIVE subanalysis . AIDS Patient Care and STDs vol. 28 , ( 4 ) 168 - 175 .
Wilkins E, Moyle G, Orkin C, Fisher M, Johnson M, Arribas J, Van Lunzen J, Garner W et al. ( 2014 ) . STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA <= 100,000 copies/mL through week 96 . HIV MEDICINE . vol. 15 , 115 - 116 .
Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C et al. ( 2014 ) . The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations . HIV Medicine vol. 15 , ( 5 ) 311 - 316 .
Orkin C, Clumeck N, Girard P-M, Henry K, Gathe J, Rockstroh J, DeJesus E, Yau S et al. ( 2014 ) . Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients . HIV MEDICINE . vol. 15 , 114 - 114 .
O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M et al. ( 2014 ) . Failure to achieve a CD4<sup>+</sup> cell count response on combination antiretroviral therapy despite consistent viral load suppression . AIDS vol. 28 , ( 6 ) 919 - 924 .
Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Papanastasopoulos P et al. ( 2014 ) . HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era . AIDS vol. 28 , ( 5 ) 689 - 697 .
Huntington S, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey P et al. ( 2014 ) . Response to antiretroviral therapy (ART): Comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women . BMC Infectious Diseases vol. 14 , ( 1 )
Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, Collins S, Cwynarski K et al. ( 2014 ) . British HIV Association guidelines for HIV-associated malignancies 2014 . HIV Medicine vol. 15 , ( S2 ) 1 - 92 .
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S et al. ( 2014 ) . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight) . HIV Medicine vol. 15 , ( S1 ) 1 - 6 .
Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al. ( 2014 ) . Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO) . Antiviral Therapy vol. 19 , ( 2 ) 191 - 200 .
Thornhill J, Mandersloot G, Bath R, Orkin C ( 2014 ) . Erratum: Opt-out HIV testing in adult critical care units (Lancet (2014) 383 (1460)) . The Lancet vol. 383 , ( 9930 )
May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M et al. ( 2014 ) . Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy . AIDS vol. 28 , ( 8 ) 1193 - 1202 .
Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H et al. ( 2014 ) . Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan . Journal of Virology vol. 88 , ( 17 ) 9864 - 9876 .
Lodi S, Del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S et al. ( 2014 ) . Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries . AIDS vol. 28 , ( 16 ) 2461 - 2473 .
Thornhill J, Mandersloot G, Bath R, Orkin C ( 2014 ) . Opt-out HIV testing in adult critical care units . The Lancet vol. 383 , ( 9927 )
Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y et al. ( 2014 ) . Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz . Journal of Antimicrobial Chemotherapy vol. 69 , ( 4 ) 1090 - 1097 .
Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES et al. ( 2014 ) . Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials . HEPATOLOGY . vol. 60 , 295A - 296A .
Arasteh K, Drulak M, Guo J, Livrozet JM, Orkin C, Quinson AM, Ward D ( 2014 ) . TRANxITION 144 week results: Switching virologically stable HIV patients from immediate-release nevirapine (NVP IR) to extended-release NVP (XR) . Journal of AIDS and Clinical Research vol. 5 , ( 4 )
Orkin C, Wohl DA, Williams A, Deckx H ( 2014 ) . Vitamin D deficiency in HIV: A shadow on long-term management? . AIDS Reviews vol. 16 , ( 2 ) 59 - 74 .
Molina JM, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M ( 2014 ) . Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤100000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials . HIV Medicine vol. 15 , ( 1 ) 57 - 62 .
Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H et al. ( 2013 ) . 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study . Antiviral Therapy vol. 18 , ( 7 ) 905 - 913 .
Boffito M, Fox J, Bowman C, Fisher M, Orkin C, Wilkins E, Jackson A, Pleguezuelos O et al. ( 2013 ) . Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial . Vaccine vol. 31 , ( 48 ) 5680 - 5686 .
Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A et al. ( 2013 ) . British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013 . HIV Medicine vol. 14 , ( SUPPL4 ) 1 - 71 .
Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT, Aitken C et al. ( 2013 ) . Persistence of HIV-1 transmitted drug resistance mutations . Journal of Infectious Diseases vol. 208 , ( 9 ) 1459 - 1463 .
Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F et al. ( 2013 ) . Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure . PLoS ONE vol. 8 , ( 9 )
Wallis E, Saunders J, Orkin C ( 2013 ) . P2.042 An Audit of HIV Testing Rates in Patients Admitted with Pneumonia Pre- and Post- Implementation of Opt-Out HIV Testing For Acute Medical Admissions . Sexually Transmitted Infections vol. 89 , ( Suppl 1 )
Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al. ( 2013 ) . HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA . HAEMATOLOGICA . vol. 98 , 129 - 129 .
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B et al. ( 2013 ) . Effects of age on antiretroviral plasma drug concentration in hivinfected subjects undergoing routine therapeutic drug monitoring . Journal of Antimicrobial Chemotherapy vol. 68 , ( 6 ) 1354 - 1359 .
Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D et al. ( 2013 ) . Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: The effect of a nucleoside backbone . Antiviral Therapy vol. 18 , ( 2 ) 213 - 219 .
Tariq S, Bath R, Tillett S, Nori A, Saunders J, Mandersloot G, Orkin C ( 2013 ) . Opt-out HIV testing within intensive care in a large urban hospital: an innovative testing initiative . HIV MEDICINE . vol. 14 , 46 - 46 .
Orkin C, Rockstroh J, DeJesus E, Henry K, Molina J, Gathe J, Wei X, Fordyce M et al. ( 2013 ) . Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients . HIV MEDICINE . vol. 14 , 56 - 56 .
Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ et al. ( 2013 ) . Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials . AIDS vol. 27 , ( 6 ) 939 - 950 .
Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, Orkin C, Fisher M et al. ( 2013 ) . NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: Integrated analysis of two phase III, randomized, controlled trials . AIDS Research and Therapy vol. 10 , ( 1 )
Orkin C, Dejesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M et al. ( 2013 ) . Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial . HIV Medicine vol. 14 , ( 1 ) 49 - 59 .
Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N et al. ( 2013 ) . Neurocognitive function in HIV infected patients on antiretroviral therapy . PLoS One vol. 8 , ( 4 )
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al. ( 2013 ) . Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study . The Lancet vol. 381 , ( 9868 ) 735 - 743 .
Cresswell F, Gothard A, Cevik M, Haidari G, Alexander H, Katsarolis I, McGinty T, Wolujewic A et al. ( 2013 ) . Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera (R)) in hepatitis C-HIV coinfection . ANTIVIRAL THERAPY . vol. 18 , A61 - A61 .
Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ et al. ( 2012 ) . Disease progression in HIV-1-infected viremic controllers . Journal of Acquired Immune Deficiency Syndromes vol. 61 , ( 4 ) 407 - 416 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2012 ) . HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era . Journal of Clinical Oncology vol. 30 , ( 33 ) 4111 - 4116 .
Molina J, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M ( 2012 ) . Rilpivirine efficacy, virology and safety in ARV treatment‐naïve patients with viral load≤100,000 HIV‐1 RNA c/mL: ECHO and THRIVE 96‐week results . Journal of the International AIDS Society . vol. 15 , 1 - 2 .
Arastéh K, Drulak M, Guo J, Livrozet J, Orkin C, Quinson A, Ward D ( 2012 ) . TRANxITION 144‐week results: switching virologically stable HIV patients from immediate‐release nevirapine (NVP IR) to extended‐release NVP (XR) . Journal of the International AIDS Society . vol. 15 , 1 - 1 .
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S et al. ( 2012 ) . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 . HIV medicine vol. 13 , 1 - 85 .
UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL et al. ( 2012 ) . Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study . BMJ vol. 345 ,
Nelson M, Amaya G, Clumeck N, Arns da cunha C, Jayaweera D, Junod P, Li T, Tebas P et al. ( 2012 ) . Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials . Journal of Antimicrobial Chemotherapy vol. 67 , ( 8 ) 2020 - 2028 .
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ et al. ( 2012 ) . Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial . JAMA - Journal of the American Medical Association vol. 308 , ( 4 ) 353 - 361 .
DeJesus E, Orkin C, Rockstroh J, Molina J-M, White K, Wei X, Plummer A, Kearney B et al. ( 2012 ) . Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks . HIV MEDICINE . vol. 13 , 9 - 9 .
Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D et al. ( 2012 ) . Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor . Journal of Antimicrobial Chemotherapy vol. 67 , ( 4 ) 995 - 1000 .
Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al. ( 2012 ) . HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . HIV MEDICINE vol. 13 , 5 - 5 .
Orkin C, Arribas J, Hodder S, Stellbrink HJ, Vanveggel S, Deckx H, Stevens M ( 2012 ) . Incidence of rash in the 96-week analysis of the pooled Phase III randomised double-blind ECHO and THRIVE trials . HIV MEDICINE . vol. 13 , 50 - 50 .
Dhairyawan R, Lowe S, Ncube B, Jones A, Strachen S, Apea V, Orkin C ( 2012 ) . The first 9 months: the lost to follow up (LTFU) clinic is born. A sustained approach to re-engaging patients . HIV MEDICINE . vol. 13 , 77 - 77 .
Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E et al. ( 2012 ) . Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200mg twice daily to nevirapine extended release 400mg once daily (TRANxITION) . HIV Medicine vol. 13 , ( 4 ) 236 - 244 .
Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y et al. ( 2012 ) . Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial . Journal of Antimicrobial Chemotherapy vol. 67 , ( 3 ) 685 - 690 .
Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D et al. ( 2012 ) . Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? . Journal of Infectious Diseases vol. 205 , ( 4 ) 540 - 547 .
Dhairyawan R, Longwill S, Orkin C, Montoto S ( 2012 ) . An innovative joint approach to HIV and lymphoma care . Sexually Transmitted Infections vol. 88 , ( 1 )
Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P et al. ( 2012 ) . British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 . HIV Medicine vol. 13 , ( 1 ) 1 - 44 .
Orkin C, Nelson M, Katlama C, Morlat P, Furrer H, Van Delft Y, Janssen M, Hill A et al. ( 2012 ) . Changes in patient-reported neuropsychiatric outcomes during the SENSE trial: First-line treatment with two nucleoside analogues plus etravirine or efavirenz . Health Outcomes Research in Medicine vol. 3 , ( 3 )
Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A et al. ( 2012 ) . Non-uptake of highly active antiretroviral therapy among patients with a CD4 count &lt;350 cells/μL in the GBR . HIV Medicine vol. 13 , ( 1 ) 73 - 78 .
Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G ( 2011 ) . Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration . Journal of Clinical Virology vol. 52 , ( 4 ) 367 - 369 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era . BLOOD . vol. 118 , 1557 - 1557 .
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. ( 2011 ) . HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era, . Blood vol. 118 , ( 21 ) 3646 - 3646 .
Hughes RA, Sterne JAC, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J et al. ( 2011 ) . Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study . HIV Medicine vol. 12 , ( 10 ) 583 - 593 .
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A et al. ( 2011 ) . Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study . BMJ (Online) vol. 343 , ( 7829 )
Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T et al. ( 2011 ) . Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study . Antiviral Therapy vol. 16 , ( 6 ) 805 - 814 .
Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al. ( 2011 ) . Authors' response to Drs Scourfield, Jackson and Nelson . HIV Medicine vol. 12 , ( 7 ) 450 - 451 .
Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al. ( 2011 ) . Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: Late presenters vs. late starters . HIV Medicine vol. 12 , ( 5 ) 289 - 298 .
Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G ( 2011 ) . Successful treatment of acute hepatitis C virus in a cohort of HIV-positive patients . HIV MEDICINE . vol. 12 , 43 - 43 .
Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ et al. ( 2011 ) . N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients . AIDS vol. 25 , ( 5 ) 651 - 657 .
UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M et al. ( 2011 ) . HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era . Eur J Neurol vol. 18 , ( 3 ) 527 - 534 .
Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al. ( 2011 ) . Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease . Neurology vol. 76 , ( 8 ) 693 - 700 .
Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, Lathouwers E, Spinosa-Guzman S ( 2010 ) . ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults . Journal of the International AIDS Society vol. 13 , ( Suppl 4 )
Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A et al. ( 2010 ) . Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection . Journal of General Virology vol. 91 , ( 11 ) 2794 - 2803 .
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G et al. ( 2010 ) . Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study . Clinical Infectious Diseases vol. 51 , ( 8 ) 963 - 972 .
Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P et al. ( 2010 ) . Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations . HIV Medicine vol. 11 , ( 7 ) 432 - 438 .
Lodwick RK, Sabin CA, Porter K, Ledergerber B, Van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A et al. ( 2010 ) . Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study . The Lancet vol. 376 , ( 9738 ) 340 - 345 .
Alesandro CL, Dunn D, Pillay D, Sabin CA, Fearnhill E, Gerettsabini AM, Hill T, Kaye S et al. ( 2010 ) . Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy . Clinical Infectious Diseases vol. 50 , ( 9 ) 1275 - 1285 .
Deayton J, Bibby D, Orkin C, O'Sullivan E, McKnight A, Clark D ( 2010 ) . Inter-clade dual HIV-1 infection in the UK - an emerging phenomenon .
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M et al. ( 2010 ) . Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma . AIDS vol. 24 , ( 6 ) 851 - 856 .
Orkin C, Sadiq ST, Rice L, Jackson F ( 2010 ) . Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B5701 in HIV-1-infected UK subjects . HIV Medicine vol. 11 , ( 3 ) 187 - 192 .
Tavel JA, Babiker A, Carey C, Fisher M, Fox L, Gey D, Lopardo GD, Lopez JC et al. ( 2010 ) . Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study . PLoS ONE vol. 5 , ( 2 )
Gilson R, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K et al. ( 2010 ) . Discordant responses on starting highly active antiretroviral therapy: Suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study . HIV Medicine vol. 11 , ( 2 ) 152 - 160 .
Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D et al. ( 2010 ) . Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals . PLoS ONE vol. 5 , ( 1 )
Orkin C, Wang J, Bergin C, Molina JM, Lazzarin A, Cavassini M, Esser S, Gómez Sirvent JL et al. ( 2010 ) . An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe . Pharmacogenetics and Genomics vol. 20 , ( 5 ) 307 - 314 .
Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M et al. ( 2010 ) . Data linkage reduces loss to follow-up in an observational HIV cohort study . Journal of Clinical Epidemiology vol. 63 , ( 10 ) 1101 - 1109 .
Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A et al. ( 2010 ) . The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - Trends in HCV testing and the impact of HCV on HIV treatment outcomes . Journal of Viral Hepatitis vol. 17 , ( 8 ) 569 - 577 .
Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B et al. ( 2009 ) . Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? . AIDS vol. 23 , ( 18 ) 2507 - 2515 .
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al. ( 2009 ) . Factors influencing lopinavir and atazanavir plasma concentration . Journal of Antimicrobial Chemotherapy vol. 65 , ( 1 ) 129 - 137 .
Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K et al. ( 2009 ) . Is 1 alanine transaminase &gt;200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study . Journal of Acquired Immune Deficiency Syndromes vol. 52 , ( 3 ) 391 - 396 .
Dreja H, O'Sullivan E, Pade C, Aubin K, Isaksen A, D'Souza C, Hand J, Orkin C et al. ( 2009 ) . P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients . Retrovirology vol. 6 , ( SUPPL. 3 )
Groves KC, Bibby D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg AJ, McKnight T ( 2009 ) . P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts . Retrovirology vol. 6 , ( SUPPL. 3 )
Khachi H, O'Connell R, Ladenheim D, Orkin C ( 2009 ) . Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection . Journal of Antimicrobial Chemotherapy vol. 64 , ( 4 ) 871 - 873 .
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T et al. ( 2009 ) . Virological response to initial antiretroviral regimens containing abacavir or tenofovir . Journal of Infectious Diseases vol. 200 , ( 5 ) 710 - 714 .
Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H et al. ( 2009 ) . A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals . Journal of Acquired Immune Deficiency Syndromes . vol. 51 , 562 - 568 .
Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L et al. ( 2009 ) . CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK . Haematologica vol. 94 , ( 6 ) 875 - 880 .
Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C et al. ( 2009 ) . The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy . HIV Medicine vol. 10 , ( 1 ) 35 - 43 .
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al. ( 2008 ) . Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Assochited Burkitt's Lymphorna (BL) . BLOOD . vol. 112 , 1235 - 1236 .
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al. ( 2008 ) . Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt’s Lymphoma (BL) . Blood vol. 112 , ( 11 ) 3612 - 3612 .
Couto-Parada X, Lee A, Ushiro-Lumb I, Anderson J, Baily G, Limb S, Noble H, Orkin C et al. ( 2008 ) . Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantification . Journal of the International AIDS Society vol. 11 , ( Suppl 1 )
Sabin CA, Lee KJ, Dunn D, Porter K, Bansi RGL, Hill T, Phillips AN, Schwenk A et al. ( 2008 ) . Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: Multicentre cohort study: The United Kingdom Collaborative HIV Cohort (CHIC) Study . AIDS . vol. 22 , 1943 - 1950 .
Ladenheim D, Horn O, Werneke U, Phillpot M, Murungi A, Theobald N, Orkin C ( 2008 ) . Potential health risks of complementary alternative medicines in HIV patients . HIV Medicine vol. 9 , ( 8 ) 653 - 659 .
El-Sadr WM, Grund B, Neaton JD, Neuhaus J, Cohen CJ, Darbyshire J, Babiker A, Emery S et al. ( 2008 ) . Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial . Annals of Internal Medicine vol. 149 , ( 5 ) 289 - 299 .
Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al. ( 2008 ) . Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication . Antiviral Therapy vol. 13 , ( 5 ) 675 - 685 .
Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al. ( 2008 ) . CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S LYMPHOMA (BL) . HAEMATOLOGICA . vol. 93 , 393 - 393 .
Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN et al. ( 2008 ) . Inferior clinical outcome of the CD4<sup>+</sup> cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4<sup>+</sup> cell counts and HIV RNA levels during follow-up . Journal of Infectious Diseases vol. 197 , ( 8 ) 1145 - 1155 .
Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B et al. ( 2008 ) . Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study . Journal of Infectious Diseases vol. 197 , ( 8 ) 1133 - 1144 .
Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J et al. ( 2008 ) . Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 cells/mm3 . Journal of Acquired Immune Deficiency Syndromes vol. 47 , ( 2 ) 202 - 205 .
Anderson J, Babiker A, Delpech V, Dunn D, Easterbrook P, Fisher M, Gazzard B, Gilson R et al. ( 2008 ) . Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? . AIDS vol. 22 , ( 3 ) 349 - 356 .
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G et al. ( 2008 ) . Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK . HIV Medicine vol. 9 , ( 1 ) 47 - 56 .
Bower M, Powles T, Williams S, Newsom Davis T, Atkins M, Montoto S, Orkin C, Webb A et al. ( 2007 ) . Brief communication: Rituximab in HIV-associated multicentric Castleman disease . Annals of Internal Medicine vol. 147 , ( 12 ) 836 - 839 .
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T et al. ( 2007 ) . Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study . Lancet vol. 370 , ( 9603 ) 1923 - 1928 .
Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M ( 2007 ) . Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4] . Blood vol. 110 , ( 12 ) 4132 - 4133 .
Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C et al. ( 2007 ) . HIV diagnosis at CD4 count above 500 cells/mm<sup>3</sup> and progression to below 350 cells/mm<sup>3</sup> without antiretroviral therapy . Journal of Acquired Immune Deficiency Syndromes vol. 46 , ( 3 ) 275 - 278 .
Gupta RK, Loveday C, Kalidindi U, Lechelt M, Skinner C, Orkin C ( 2007 ) . Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice . International Journal of STD and AIDS vol. 18 , ( 9 ) 630 - 632 .
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M et al. ( 2007 ) . Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count . AIDS vol. 21 , ( 13 ) 1717 - 1721 .
Burns S, Cameron S, Cane P, Chrystie I, Churchill D, Delpech V, Pillay D, Dunn D et al. ( 2007 ) . Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom . AIDS vol. 21 , ( 8 ) 1035 - 1039 .
Stöhr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P et al. ( 2007 ) . CD4 cell count and initiation of antiretroviral therapy: Trends in seven UK centres, 1997-2003 . HIV Medicine vol. 8 , ( 3 ) 135 - 141 .
Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P et al. ( 2007 ) . Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures . AIDS vol. 21 , ( 11 ) 1423 - 1430 .
Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G et al. ( 2005 ) . A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study) . Journal of Antimicrobial Chemotherapy vol. 55 , ( 2 ) 246 - 251 .
Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B ( 2004 ) . A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART) . Journal of Antimicrobial Chemotherapy vol. 53 , ( 3 ) 501 - 505 .
Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, Imami N, Gazzard BG ( 2003 ) . Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection . AIDS vol. 17 , ( 9 ) 1411 - 1413 .